UBS Knock-Out IDP/ DE000UM1X1D1 /
01/08/2024 12:05:50 | Chg.-0.021 | Bid12:47:48 | Ask12:47:48 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.222EUR | -8.64% | - Bid Size: - |
- Ask Size: - |
BIOGEN INC. DL -,000... | 191.6138 - | 31/12/2078 | Call |
GlobeNewswire
28/06
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire
24/06
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire
10/06
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire
03/06
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire
30/05
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire
22/05
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
16/05
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
15/05
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
25/04
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
23/04
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
06/03
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
04/03
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
23/02
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
12/02
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
GlobeNewswire
08/02
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors